1. Home
  2. ARAY vs SCYX Comparison

ARAY vs SCYX Comparison

Compare ARAY & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Accuray Incorporated

ARAY

Accuray Incorporated

HOLD

Current Price

$0.28

Market Cap

39.3M

Sector

Health Care

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$4.35

Market Cap

44.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARAY
SCYX
Founded
1990
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.3M
44.0M
IPO Year
2006
2014

Fundamental Metrics

Financial Performance
Metric
ARAY
SCYX
Price
$0.28
$4.35
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$3.50
$3.00
AVG Volume (30 Days)
1.8M
94.7K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
87.50
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.58
$608.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$0.57
52 Week High
$2.10
$5.62

Technical Indicators

Market Signals
Indicator
ARAY
SCYX
Relative Strength Index (RSI) 47.93 63.96
Support Level $0.28 $0.67
Resistance Level $0.36 $5.62
Average True Range (ATR) 0.03 0.31
MACD 0.00 -0.05
Stochastic Oscillator 47.37 77.27

Price Performance

Historical Comparison
ARAY
SCYX

About ARAY Accuray Incorporated

Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: